Oaktree Weighs Stake in Bankrupt Fund
Oaktree Capital Management is considering a $300 million investment in a bankrupt biotechnology fund that Russian billionaire Dmitry Rybolovlev’s family trust is seeking to shut down, Steven Church reports.
Venture capital fund ATP Life Science Ventures and seven of its portfolio companies filed for bankruptcy in December in Delaware after a months-long court fight with Rybolovlev’s trust. The family trust has invested $2.4 billion through ATP, which is run independently by biotech entrepreneur Seth Harrison.
Before the filing, Rybolovlev’s trust had been trying to remove Harrison and wind down the fund. The trust is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.